Related Experiment Video
Updated: May 21, 2026
07:40
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
NHLBI clinical trials workshop: an executive summary
Gang Zheng1, Colin O Wu, Song Yang
1Office of Biostatistics Research, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD 20892, U.S.A. zhengg@nhlbi.nih.gov
Statistics in Medicine
|June 27, 2012
Summary
This report summarizes a workshop on clinical trials, covering their history, Bayesian methods, surrogate endpoints, adaptive designs, and comparative effectiveness research. Key discussions focused on advancing clinical trial methodologies for future research.
Area of Science:
- Clinical Trials Research
- Biostatistics
- Medical Research Methodology
Background:
- The National Heart, Lung and Blood Institute (NHLBI) convened a workshop titled 'Clinical Trials: Past, Present and Future' on September 13-14, 2010.
- The workshop aimed to discuss the evolution and future directions of clinical trial methodologies.
Observation:
- Discussions encompassed the historical context of clinical trials at NHLBI.
- Key topics included Bayesian clinical trials, surrogate endpoints, reporting standards, and data handling.
- Advanced methodologies such as flexible and adaptive trial designs, personalized medicine, genomic trials, and comparative effectiveness research were also covered.
Findings:
- The workshop provided a comprehensive overview of current and emerging trends in clinical trial design and execution.
- Insights were shared on optimizing clinical trial processes, from design to data analysis and reporting.
- The event highlighted the importance of innovative approaches to address complex research questions.
Implications:
- The summarized discussions offer valuable insights for researchers and stakeholders involved in clinical trials.
- The findings can inform the development of more efficient, effective, and patient-centered clinical research strategies.
- This report serves as a resource for understanding the trajectory of clinical trials and their future potential.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:19Overview of Biostatistics in Health Sciences
Biostatistics involves the application of statistical techniques to scientific research in health-related fields, including biology and public health. These techniques are essential for designing studies, collecting data, and analyzing it to draw meaningful conclusions. Given the complexity of biological processes, particularly in studies involving human subjects, biostatistical methods are crucial for effectively organizing and interpreting data that might otherwise obscure underlying patterns...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...